Pantoprazole 40 MG versus omeprazole 20 MG in the treatment of reflux oesophagitis: Results of a French multicentric double-blind comparative trial

Vicari, Fernand; Belin, J; Marek, L.

doi:10.1016/s0016-5085(98)81314-0

Cited by 11 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical efficacy and safety studies with pantoprazole (40 mg daily) have consistently shown healing rates for oesophageal erosions of 70–80% following 4 weeks of treatment and of > 80% after 8 weeks. These rates are superior to those obtained with ranitidine, 11–13 and comparable to those for omeprazole 14–16 and lansoprazole 17 ,. 18 Clinical studies have indicated that pantoprazole is effective for the rapid healing of erosive oesophagitis, 19 as well as in relieving symptoms in patients with mild erosive disease 20 ,.…”

Section: Introductionmentioning

confidence: 52%

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Kovacs

Wilcox

DeVault

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease. Aim: To compare the efficacy and safety of pantoprazole vs. nizatidine for the treatment of symptomatic gastrooesophageal reflux disease and endoscopically documented erosive oesophagitis (grade ‡ 2). Methods: A multicentre, double-blind, randomized, active-controlled study (221 patients) was performed to compare 20 and 40 mg pantoprazole daily with nizatidine 150 mg b.d. (maximum, 8 weeks). The primary end-point was endoscopic healing of erosive oesophagitis (grade 1 or 0). The secondary end-point was symptomatic improvement. Results: Healing averaged 61%, 64% and 22% for pantoprazole 20 mg, pantoprazole 40 mg and nizatidine

show abstract

Section: Introductionmentioning

confidence: 52%

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Kovacs

Wilcox

DeVault

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…L30 may be superior to O20 in preventing or reducing meal-induced heartburn symptoms 3 hours after a meal, presumably because of the greater bioavailability and more rapid onset of action of a single dose of L. R20 is comparable to O20 in treating persons with grades 2 to 4 erosive esophagitis (Table 1) [17]. Healing rates of erosive esophagitis are generally comparable between L and O, although there may be a trend for faster symptom relief with L. No difference has been observed in esophagitis healing rates or for rates of symptom relief with P40 and O20 [19]. Equivalence in healing and symptom relief has also been reported for R20 and O20.…”

Section: Gastroesophageal Reflux Diseasementioning

confidence: 98%

Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole

Thomson

2000

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Four proton pump inhibitors (PPIs) are currently marketed in various parts of the world, and all of these (lansoprazole, omeprazole, pantoprazole, and rabeprazole) are available for prescription use in the United States. As a therapeutic group, the PPIs are highly useful for the relief of symptoms and healing of gastroesophageal reflux disease, gastric and duodenal ulcer disease, eradication of Helicobacter pylori infection, prevention and treatment of nonsteroidal anti-inflammatory drug (NSAID)-associated damage, management of hypersecretory states such as Zollinger-Ellison syndrome, and care of patients with non-variceal upper gastrointestinal bleeding, or non-ulcer dyspepsia. The pathophysiologic basis of these management benefits lies in the potent gastric acid inhibitory effects of the PPIs. There are differences between the PPIs in their pharmacokinetics, pharmacodynamics, influence by food and antacids, clinical efficacy, and potential for drug interactions. It is not always clear whether these often subtle variations are necessarily of clinical importance. The physician's choice of one PPI over another must rest with her/his interpretation of the clinical importance of the generally small differences between PPIs, their approval for treatment of specific clinical indications within the physician's practice jurisdiction, and the strength of the evidence based on the quantity and quality of the supporting clinical trials.

show abstract

“…These events are uncommon (approximately 1%) and rarely lead to withdrawal of treatment. Data from numerous clinical trials and clinical experience confirm the short-term adverse effects of PPIs and also of pantoprazole (Fitton and Wiseman 1996; Dupas et al 1998; Richardson et al 1998; Vicari et al 1998). …”

Section: Efficacy Safety and Tolerability Of Pantoprazolementioning

confidence: 91%

Long-term management of GERD in the elderly with pantoprazole

Calabrese¹,

Fabbri²,

Febo³

2007

Clinical Interventions in Aging

View full text Add to dashboard Cite

The prevalence of gastroesophageal reflux disease (GERD) increases with age and elderly are more likely to develop severe disease. Older patients often complain of less severe or frequent heartburn than younger patients and they may present with atypical symptoms such as dysphagia, weight loss, or extraesophageal symptoms. Proton pump inhibitors (PPIs) are central in the management of GERD and are unchallenged with regards to their efficacy. They are considered safe and more effective than histamine receptor antagonists for healing esophagitis and for preventing its recurrence using a long term maintenance treatment. PPI have minimal side effects and few slight drug interactions and are considered safe for long term treatment. Pantoprazole is significantly effective both for acute and long-term treatment with excellent control of relapse and symptoms. It is well tolerated even for long-term therapy and its tolerability is optimal. Pantoprazole shows to have minimal interactions with other drugs because of a lower affinity for cytocrome P450 than older PPIs. Although the majority of elderly has concomitant illnesses and receive other drugs, this does not adversely effect the efficacy of pantoprazole because of its pharmacokinetics, which are independent of patient age. Clinical practice suggests that a low dose maintenance of PPIs should be used in older patients with GERD.

show abstract

Pantoprazole 40 MG versus omeprazole 20 MG in the treatment of reflux oesophagitis: Results of a French multicentric double-blind comparative trial

Cited by 11 publications

References 0 publications

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole

Long-term management of GERD in the elderly with pantoprazole

Contact Info

Product

Resources

About